AsianScientist (Dec. 9, 2016) – Novogene Technology Co., Ltd., a provider of genomic services and solutions, has announced that it has completed a US$75 million B round financing with China Merchants Bank Co., Ltd.’s CMB International Capital Management (Shenzhen) Co., Ltd. (CMB International), SDIC Innovation Investment Management Co., Ltd. (SDIC Innovation) and Shanghai Sigma Square Investment Center LP (Sigma Square Capital).
Novogene, headquartered in Beijing with the largest genomic sequencing center in the Asia Pacific region, has labs in Tianjin and the US, and subsidiaries or joint ventures in Hong Kong, the US, the UK and Singapore. The Series B financing will support strategic growth in Novogene’s global next-generation sequencing (NGS) service market and in clinical sequencing R&D and services.
Additionally, funds from the financing will be used to enhance operating efficiency to further strengthen the company’s leadership position in the NGS industry.
———
Source: Novogene Technologies Co. Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
